Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Corporate Profile

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor that we are evaluating in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities to overcome treatment resistance and deliver superior clinical benefit compared the SoC.

Company Overview (button) - March 2023
Recent News
Mar 6, 2023

- SAB includes recognized leaders with expertise in oncology drug development, pharmaceutical industry dynamics and translational research – - SAB will continue to provide insight and guidance...

Mar 2, 2023

Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective response rate, durability and...

Feb 27, 2023

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of...

More >

Stock Information
NASDAQCRDF
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@cardiffoncology.com

Contact

Events
March 6, 2023 - March 8, 2023
8:00am - 5:00pm EST

Cardiff Oncology management will participate in a corporate panel discussion and 1x1 investor meetings at the TD Cowen 43rd Annual Health Care Conference, which is taking place at the Boston...

January 18, 2023
1:30pm - 2:00pm EST

Cardiff Oncology management will participate in a firesidie chat at the B. Riley Securities' 3rd Annual Oncology Conference, which is taking place virtually on January 18-19, 2023. Details of the...

December 7, 2022
3:00pm - 3:15pm EST

Cardiff Oncology management will participate in a virtual fireside chat at The JMP Secutities Hematology and Oncology Summit on Wednesday, December 7th from 3:00 - 3:15 Pm ET. A link to the...